Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Osteoclast differentiation and activation.

Boyle WJ, Simonet WS, Lacey DL.

Nature. 2003 May 15;423(6937):337-42. Review.

PMID:
12748652
2.

Vitamin E decreases bone mass by stimulating osteoclast fusion.

Fujita K, Iwasaki M, Ochi H, Fukuda T, Ma C, Miyamoto T, Takitani K, Negishi-Koga T, Sunamura S, Kodama T, Takayanagi H, Tamai H, Kato S, Arai H, Shinomiya K, Itoh H, Okawa A, Takeda S.

Nat Med. 2012 Mar 4;18(4):589-94. doi: 10.1038/nm.2659. Erratum in: Nat Med. 2012 Sep;18(9):1445.

PMID:
22388090
3.

Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis.

Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A, Mizoguchi T, Kikuchi Y, Takada I, Kato S, Kani S, Nishita M, Marumo K, Martin TJ, Minami Y, Takahashi N.

Nat Med. 2012 Feb 19;18(3):405-12. doi: 10.1038/nm.2653.

PMID:
22344299
4.

Regulators of osteoclast differentiation and cell-cell fusion.

Miyamoto T.

Keio J Med. 2011;60(4):101-5. Review.

5.

Regulatory mechanisms of osteoblast and osteoclast differentiation.

Katagiri T, Takahashi N.

Oral Dis. 2002 May;8(3):147-59. Review.

PMID:
12108759
6.

VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors.

Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Lu X, Haffty BG, Pantel K, Massagué J, Kang Y.

Cancer Cell. 2011 Dec 13;20(6):701-14. doi: 10.1016/j.ccr.2011.11.002. Epub 2011 Dec 1.

7.

New regulation mechanisms of osteoclast differentiation.

Nakashima T, Takayanagi H.

Ann N Y Acad Sci. 2011 Dec;1240:E13-8. doi: 10.1111/j.1749-6632.2011.06373.x. Review.

PMID:
22360322
8.

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.

Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM.

Nature. 2010 Nov 4;468(7320):98-102. doi: 10.1038/nature09387. Epub 2010 Sep 29.

9.

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ.

Cell. 1998 Apr 17;93(2):165-76.

10.

The transcription factor Jdp2 controls bone homeostasis and antibacterial immunity by regulating osteoclast and neutrophil differentiation.

Maruyama K, Fukasaka M, Vandenbon A, Saitoh T, Kawasaki T, Kondo T, Yokoyama KK, Kidoya H, Takakura N, Standley D, Takeuchi O, Akira S.

Immunity. 2012 Dec 14;37(6):1024-36. doi: 10.1016/j.immuni.2012.08.022. Epub 2012 Nov 29.

11.

Spleen serves as a reservoir of osteoclast precursors through vitamin D-induced IL-34 expression in osteopetrotic op/op mice.

Nakamichi Y, Mizoguchi T, Arai A, Kobayashi Y, Sato M, Penninger JM, Yasuda H, Kato S, DeLuca HF, Suda T, Udagawa N, Takahashi N.

Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):10006-11. doi: 10.1073/pnas.1207361109. Epub 2012 Jun 5.

12.

Osteoclast-osteoblast communication.

Matsuo K, Irie N.

Arch Biochem Biophys. 2008 May 15;473(2):201-9. doi: 10.1016/j.abb.2008.03.027. Epub 2008 Mar 29. Review.

PMID:
18406338
13.

Differentiation of activated monocytes into osteoclast-like cells on a hydroxyapatite substrate: an in vitro study.

Narducci P, Nicolin V.

Ann Anat. 2009 Oct;191(4):349-55. doi: 10.1016/j.aanat.2009.02.009. Epub 2009 Apr 24.

PMID:
19447592
14.

Matrix-embedded cells control osteoclast formation.

Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA.

Nat Med. 2011 Sep 11;17(10):1235-41. doi: 10.1038/nm.2448.

15.

The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.

Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, Collins L, Piwnica-Worms D, Steinberg TH, Novack DV, Conley PB, Hurchla MA, Rogers M, Weilbaecher KN.

J Clin Invest. 2012 Oct;122(10):3579-92. doi: 10.1172/JCI38576. Epub 2012 Sep 17.

16.

TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival.

Gingery A, Bradley EW, Pederson L, Ruan M, Horwood NJ, Oursler MJ.

Exp Cell Res. 2008 Sep 10;314(15):2725-38. doi: 10.1016/j.yexcr.2008.06.006. Epub 2008 Jun 13.

17.

The osteoclast, bone remodelling and treatment of metabolic bone disease.

Boyce BF, Rosenberg E, de Papp AE, Duong LT.

Eur J Clin Invest. 2012 Dec;42(12):1332-41. doi: 10.1111/j.1365-2362.2012.02717.x. Epub 2012 Sep 23. Review.

PMID:
22998735
18.

Osteoclast precursors, RANKL/RANK, and immunology.

Xing L, Schwarz EM, Boyce BF.

Immunol Rev. 2005 Dec;208:19-29. Review.

PMID:
16313338
19.

New roles of osteoblasts involved in osteoclast differentiation.

Yamashita T, Takahashi N, Udagawa N.

World J Orthop. 2012 Nov 18;3(11):175-81. doi: 10.5312/wjo.v3.i11.175.

20.

Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation.

Lotinun S, Kiviranta R, Matsubara T, Alzate JA, Neff L, Lüth A, Koskivirta I, Kleuser B, Vacher J, Vuorio E, Horne WC, Baron R.

J Clin Invest. 2013 Feb;123(2):666-81. doi: 10.1172/JCI64840. Epub 2013 Jan 16.

Supplemental Content

Support Center